AbbVie buys United's Priority Review voucher

United Therapeutics Corp. (NASDAQ:UTHR) said it sold a rare pediatric disease Priority Review voucher to AbbVie Inc. (NYSE:ABBV) for $350 million. AbbVie spokesperson Adelle Infante declined to disclose the company's

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE